Make earnings with no risk
Automated AI-driven system makes the trades, you earn the money
Join now

Sanofi Q4 Results


Sales Forecast

Analysts anticipate that French pharmaceutical giant Sanofi will report fourth-quarter sales of €11.04 billion ($11.97 billion), according to consensus estimates provided by the company. This is an increase from sales of €10.725 billion reported in the same period of the previous year.

Business Profit Forecast

The company’s preferred metric, business net profit, is predicted to be €2.14 billion, in line with the net profit reported in the year-earlier period. Business net profit excludes exceptional items.

What to Watch

1. Outlook for 2024 and 2025: In October, Sanofi provided a preliminary outlook for 2024 and 2025. They guided for a decline in business earnings per share at constant currency this year, followed by a rebound in 2025 driven by continued sales growth. There is a key debate among investors regarding Sanofi’s growth prospects beyond 2024 and the potential impact of shifting towards higher-margin products on its bottom line.

2. Dupixent’s Growth Potential: Dupixent, an anti-inflammatory drug developed in collaboration with Regeneron Pharmaceuticals, has been a significant contributor to Sanofi’s growth in recent quarters. The company expects sales of Dupixent to surpass €10 billion in 2023, potentially leading to upgrades in consensus estimates for Sanofi’s earnings.

3. Diversifying Revenue Sources: Aside from Dupixent, Sanofi has other drugs in its pipeline that could diversify its sources of revenue growth. These include Altuviiio, a hemophilia treatment, Beyfortus injection for the prevention of respiratory syncytial virus (RSV), and Tzield, a diabetes drug. These next-generation products have the potential to boost sales and enhance Sanofi’s market presence.

Group 1 Automotive to Reduce U.K. Workforce by 10%

Previous article

BNP Paribas to Report Q4 Results

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in News